Uptake of the OMERACT-OARSI hip and knee osteoarthritis core outcome set: Review of randomized controlled trials from 1997 to 2017

Toby O. Smith, Michael Mansfield, Gillian A. Hawker, David J. Hunter, Lyn M. March, Maarten Boers, Beverley J. Shea, Robin Christensen, Francis Guillemin, Caroline B. Terwee, Paula R. Williamson, Ewa M. Roos, Richard F. Loeser, Thomas J. Schnitzer, Margreet Kloppenburg, Tuhina Neogi, Christoph H. Ladel, Gurdyal Kalsi, Ulrike Kaiser, Thomas W. ButtelAnne E. Ashford, Ali Mobasheri, Nigel K. Arden, Alan Tennant, Marc C. Hochberg, Maarten de Wit, Peter Tugwell, Philip G. Conaghan

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

Objective. To assess the uptake of the OMERACT-OARSI (Outcome Measures in Rheumatology- Osteoarthritis Research Society International) core outcome set (COS) domains in hip and/or knee osteoarthritis (OA) trials. Methods. There were 382 trials of hip and/or knee OA identified from the ClinicalTrial.gov registry from 1997 to 2017. Frequency of COS adoption was assessed by year and per 5-yearly phases. Results. COS adoption decreased from 61% between 1997 and 2001 to 38% between 2012 and 2016. Pain (95%) and physical function (86%) were most consistently adopted. Patient’s global assessment (48%) was the principal missing domain. Conclusion. Limited adoption of the COS domains indicates that further consideration to improve uptake is required.
Original languageEnglish
Pages (from-to)976-980
JournalJournal of Rheumatology
Volume46
Issue number8
DOIs
Publication statusPublished - 1 Aug 2019

Cite this